ZZZhi Zheng

Zhi Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhi Zheng has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Cui-Yun Yu

    University of South China

    4 shared publications
  • Hua Wei

    Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China

    4 shared publications
  • Jiahao Xie

    Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study & School of Pharmaceutical Science, Hengyang Medical School, University of South China , 28 W Changsheng Road , Hengyang 421001

    2 shared publications
  • Ying Tan

    Hunan Provincial Key Laboratory of Multi-omics And Artificial Intelligence of Cardiovascular Diseases &Department of Cardiology, The First Affiliated Hospital, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study & School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China

    2 shared publications
  • Zhenqiu Liu

    Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study & School of Pharmaceutical Science, Hengyang Medical School, University of South China , 28 W Changsheng Road , Hengyang 421001

    2 shared publications
  • Bin Wang

    Clinical Stem Cell Center Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing China

    1 shared publication

Latest Publications

  • Open Access

    Hydrogel Engineering Interventions for Precision Cartilage Regeneration: Bridging Pathological Mechanisms and Therapeutic Innovation

    by Zhi Zheng, Roujun Chen, Yaqin Lin

    Although microfracture, osteochondral transplantation, and autologous chondrocyte implantation are commonly employed, accurately replicating the natural calcified layer at the cartilage-bone interface remains challenging, leading to structural and functional impairments in regenerated cartilage. For successful cartilage regeneration, engineered therapeutic materials must be tailored to the structural and pathophysiological characteristics of cartilage injury. This necessitates the development of strategic interventions based on a comprehensive understanding of the injured structure and microenvironment, including extracellular matrix degradation, inflammatory cascades, disrupted intercellular communication, and integrated pathophysiological networks. This review systematically elucidates microenvironment evolution and molecular mechanisms post-cartilage injury while highlighting the application of injectable hydrogels and 3D printing technology as delivery vehicles for various therapeutic agents (including drugs, cells, and genes) in tissue engineering. By emphasizing their unique capacity for designing customized systems to modulate the regeneration process, this work aims to establish a cohesive theoretical framework and a clear technical roadmap for guiding the future development of precise cartilage repair solutions.


  • Top Cited Papers
    Open Access

    Pathology-guided design of injectable hydrogels for precision therapy and cartilage regeneration in osteoarthritis

    by Zhi Zheng, Jiahao Xie, Junfa Zeng, Zhan Kang, Zhenqiu Liu, Mengzhen Qi, Cuiyun Yu, Hua Wei

    Osteoarthritis (OA) is a highly prevalent degenerative joint disease whose complex pathological microenvironment and limited cartilage self-repair capacity have resulted in the absence of therapeutic approaches capable of simultaneously achieving structural reconstruction and functional recovery. Current clinical strategies face significant limitations, as conventional pharmacological treatments can only alleviate symptoms with accompanying systemic side effects, while surgical interventions often encounter challenges such as inadequate mechanical properties of repaired tissues and long-term degeneration. The precise functionalization of injectable hydrogels represents a key strategy for cartilage regeneration and the core challenge lies in integrating multiple material properties to design on-demand delivery platforms that can dynamically respond to complex pathological microenvironments in vivo. This review systematically elaborates on precision customization strategies for injectable hydrogels based on OA pathological mechanisms, focusing on how hydrogel design responds to pathological signals in the joint microenvironment to achieve on-demand and precise regulation of therapeutic agents including drugs, cells and genes. Beginning with cartilage structure and injury mechanisms, this article analyzes the limitations of existing pharmacological and surgical repair methods, then, elaborate on the multifunctional platform role of hydrogels in cartilage tissue engineering, including recent advances in mechanical design, drug loading/release behavior, inflammation regulation, stem cell delivery and gene-activated repair. Finally, it outlines challenges and future directions for smart hydrogels in cartilage regenerative medicine, aiming to provide a theoretical framework and technical pathway for integrating materials science with clinical medicine.


  • Open Access

    Hydrogel-based cardiac patches for myocardial infarction therapy: Recent advances and challenges

    by Zhenqiu Liu, Zhi Zheng, Jiahao Xie, Hua Wei, Cui-Yun Yu


  • Open Access

    Novel Approach for Cardioprotection: In Situ Targeting of Metformin via Conductive Hydrogel System

    by Ying Tan, Jierong Li, Yali Nie, Zhi Zheng

    Ischemia/reperfusion (I/R) injury following myocardial infarction is a major cause of cardiomyocyte death and impaired cardiac function. Although clinical data show that metformin is effective in repairing cardiac I/R injury, its efficacy is hindered by non-specific targeting during administration, a short half-life, frequent dosing, and potential adverse effects on the liver and kidneys. In recent years, injectable hydrogels have shown substantial potential in overcoming drug delivery challenges and treating myocardial infarction. To this end, we developed a natural polymer hydrogel system comprising methacryloylated chitosan and methacryloylated gelatin modified with polyaniline conductive derivatives. In vitro studies demonstrated that the optimized hydrogel exhibited excellent injectability, biocompatibility, biodegradability, suitable mechanical properties, and electrical conductivity. Incorporating metformin into this hydrogel significantly extended the administration cycle, mitigated mitochondrial damage, decreased abnormal ROS production, and enhanced cardiomyocyte function. Animal experiments indicated that the metformin/hydrogel system reduced arrhythmia incidence, infarct size, and improved cardiac mitochondrial and overall cardiac function, promoting myocardial repair in I/R injury. Overall, the metformin-loaded conductive hydrogel system effectively mitigates mitochondrial oxidative damage and improves cardiomyocyte function, thereby offering a theoretical foundation for the potential application of metformin in cardioprotection.


  • Open Access

    Comparative effectiveness of myocardial patches and intramyocardial injections in treating myocardial infarction with a MitoQ/hydrogel system

    by Ying Tan, Yali Nie, Lei ZhengWen, Zhi Zheng

    In cardiac tissue engineering, myocardial surface patches and hydrogel intramyocardial injections represent the two primary hydrogel-based strategies for myocardial infarction (MI) treatment. However, the comparative effectiveness of these two treatments remains uncertain. Therefore, this study aimed to compare the effects of the two treatment modalities by designing a simple and reproducible hydrogel cross-linked with γ-PGA and 4-arm-PEG-SG. To improve mitochondrial damage in cardiomyocytes (CMs) during early MI, we incorporated the mitochondria-targeting antioxidant MitoQ into the hydrogel network. The hydrogel exhibited excellent biodegradability, biocompatibility, adhesion, and injectability in vitro. The hydrogel was utilized for rat MI treatment through both patch adhesion and intramyocardial injections. In vivo results demonstrated that the slow release of MitoQ peptide from the hydrogel hindered ROS production in CM, alleviated mitochondrial damage, and enhanced CM activity within 7 days, effectively inhibiting MI progression. Both hydrogel intramyocardial injections and patches exhibited positive therapeutic effects, with intramyocardial injections demonstrating superior efficacy in terms of cardiac function and structure in equivalent treatment cycles. In conclusion, we developed a MitoQ/hydrogel system that is easily prepared and can serve as both a myocardial patch and an intramyocardial injection for MI treatment, showing significant potential for clinical applications.


  • Open Access

    Engineered cyclodextrin-based supramolecular hydrogels for biomedical applications

    by Yuqi Zhao, Zhi Zheng, Cui-Yun Yu, Hua Wei

    This review makes a comprehensive summary on the cross-linking mechanism, optimization of mechanical properties, drug loading and release modalities, and recent biological applications of CD-based supramolecular hydrogels.


  • A dual crosslinked hydrogel-mediated integrated peptides and BMSC therapy for myocardial regeneration

    by Zhi Zheng, Zheng Guo, Fengmin Zhong, Bin Wang, Li Liu, Wei Ma, Cui-Yun Yu, Hua Wei


  • ApoM-S1P Modulates Ox-LDL-Induced Inflammation Through the PI3K/Akt Signaling Pathway in HUVECs

    by Zhi Zheng, Yongzhi Zeng, Xiao Zhu, Ying Tan, Yi Li, Qian Li, Guanghui Yi

    Studies have shown that apolipoprotein M (apoM), the main carrier of sphingosine-1-phosphate (S1P), is closely related to lipid metabolism and inflammation. While there are many studies on apoM and lipid metabolism, little is known about the role of apoM in inflammation. Atherosclerosis is a chronic inflammatory process. To clarify what role apoM plays in atherosclerosis, we used oxidized low-density lipoprotein (ox-LDL) to induce an inflammatory model of atherosclerosis. Our preliminary results indicate that ox-LDL upregulates the expression of S1P receptor 2 (S1PR2) in human umbilical vein endothelial cells (HUVECs). Ox-LDL-induced HUVECs were treated with apoM-bound S1P (apoM-S1P), free S1P or apoM, and apoM-S1P was found to significantly inhibit the expression of inflammatory factors and adhesion molecules. In addition, apoM-S1P inhibits ox-LDL-induced cellular inflammation via S1PR2. Moreover, apoM-S1P induces phosphorylation of phosphatidylinositol 3-kinase (PI3K)/Akt, preventing nuclear translocation of nuclear factor-κB (NF-κB). PI3K-specific inhibitors and Akt inhibitors suppress apoM-S1P/S1PR2-induced interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) release and affect nuclear translocation of NF-κB. In conclusion, the results demonstrate for the first time that apoM-S1P inhibits ox-LDL-induced inflammation in HUVECs via the S1PR2-mediated PI3K/Akt signaling pathway. This finding may aid in the development of new treatments for atherosclerosis.